ArticleHeliyon2024
Should we routinely assess ovarian reserve in girls and young women with autoimmune thyroid disease?
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Some studies report that reproductive aged women with autoimmune thyroid disease (ATD) have a significantly higher risk of diminished ovarian reserve (OR). What is the best time to assessed OR in females with ATD? To answer this question, we assessed OR in girls and young women with ATD and reviewed the current literature regarding on the topic. Methods: The study included 70 patients with ATD, mean 14.4 ± 3.3 years, and 29 age-matched controls. Follicle-stimulating hormone (FSH), luteinizing hormone, estradiol, prolactin, thyroid stimulating hormone, free thyroxin, thyroid peroxidase antibody, thyroglobulin antibody and Anti-Mullerian Hormone (AMH), and Inhibin-B were measured in all participants, if possibly on day 3-5 of the menstrual cycle. Results: Most ATD patients were euthyroid. All participants have normal OR. We found a significantly positive correlation between AMH and Inhibin-B in ATD patients and between Inhibin-B and FSH in both groups. Conclusions: The results of our study and the literature review indicate that euthyroid adolescents with ATD do not have impaired OR. Routine evaluation of OR in adolescents with ATD does not seem necessary. But OR should be assessed in everyone with ATD and hypothyroidism, because not the presence of ATD but euthyroidism matters to OR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.